Tyrosine kinase receptors are involved in tumorigenesis; therefore, kinase inhibitors show some benefit and, to date, the multikinase inhibitors sorafenib, lenvatinib and regorafenib have been approved for the treatment of HCC [5,6,7]. Here, NTRK1 is linked to hepatocellular carcinoma.